Literature DB >> 32929214

Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis.

Seoyoung Kim1, Sang Ho Shin1, Barbara Santangelo2, Mattia Veronese2, Seung Kwan Kang3,4, Jae Sung Lee3,4, Gi Jeong Cheon3,5, Woojoo Lee6, Jun Soo Kwon7,8, Oliver D Howes9,10, Euitae Kim11,12,13.   

Abstract

Although antipsychotic drugs are effective for relieving the psychotic symptoms of first-episode psychosis (FEP), psychotic relapse is common during the course of the illness. While some FEPs remain remitted even without medication, antipsychotic discontinuation is regarded as the most common risk factor for the relapse. Considering the actions of antipsychotic drugs on presynaptic and postsynaptic dopamine dysregulation, this study evaluated possible mechanisms underlying relapse after antipsychotic discontinuation. Twenty five FEPs who were clinically stable and 14 matched healthy controls were enrolled. Striatal dopamine activity was assessed as Kicer value using [18F]DOPA PET before and 6 weeks after antipsychotic discontinuation. The D2/3 receptor availability was measured as BPND using [11C]raclopride PET after antipsychotic discontinuation. Healthy controls also underwent PET scans according to the corresponding schedule of the patients. Patients were monitored for psychotic relapse during 12 weeks after antipsychotic discontinuation. 40% of the patients showed psychotic relapse after antipsychotic discontinuation. The change in Kicer value over time significantly differed between relapsed, non-relapsed patients and healthy controls (Week*Group: F = 4.827, df = 2,253.193, p = 0.009). In relapsed patients, a significant correlation was found between baseline striatal Kicer values and time to relapse after antipsychotic discontinuation (R2 = 0.518, p = 0.018). BPND were not significantly different between relapsed, non-relapsed patients and healthy controls (F = 1.402, df = 2,32.000, p = 0.261). These results suggest that dysfunctional dopamine autoregulation might precipitate psychotic relapse after antipsychotic discontinuation in FEP. This finding could be used for developing a strategy for the prevention of psychotic relapse related to antipsychotic discontinuation.
© 2020. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32929214     DOI: 10.1038/s41380-020-00879-0

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  67 in total

1.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

2.  Stability and development of psychotic symptoms and the use of antipsychotic medication - long-term follow-up.

Authors:  D R Gotfredsen; R S Wils; C Hjorthøj; S F Austin; N Albert; R G Secher; A A E Thorup; O Mors; M Nordentoft
Journal:  Psychol Med       Date:  2017-04-06       Impact factor: 7.723

3.  Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.

Authors:  Arsime Demjaha; Robin M Murray; Philip K McGuire; Shitij Kapur; Oliver D Howes
Journal:  Am J Psychiatry       Date:  2012-11       Impact factor: 18.112

4.  First-episode psychosis: diagnostic stability over one and two years.

Authors:  Ulrik Haahr; Svein Friis; Tor K Larsen; Ingrid Melle; Jan Olav Johannessen; Stein Opjordsmoen; Erik Simonsen; Bjørn Rishovd Rund; Per Vaglum; Thomas McGlashan
Journal:  Psychopathology       Date:  2008-07-19       Impact factor: 1.944

5.  The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

Authors:  Oliver D Howes; Joseph Kambeitz; Euitae Kim; Daniel Stahl; Mark Slifstein; Anissa Abi-Dargham; Shitij Kapur
Journal:  Arch Gen Psychiatry       Date:  2012-08

6.  A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia.

Authors:  Sameer Jauhar; Matthew M Nour; Mattia Veronese; Maria Rogdaki; Ilaria Bonoldi; Matilda Azis; Federico Turkheimer; Philip McGuire; Allan H Young; Oliver D Howes
Journal:  JAMA Psychiatry       Date:  2017-12-01       Impact factor: 21.596

Review 7.  Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review.

Authors:  Craig Karson; Ruth A Duffy; Anna Eramo; Anna-Greta Nylander; Steve J Offord
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-06       Impact factor: 2.570

8.  Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis.

Authors:  Paolo Fusar-Poli; Marco Cappucciati; Grazia Rutigliano; Margaret Heslin; Daniel Stahl; Zera Brittenden; Edgardo Caverzasi; Philip McGuire; William T Carpenter
Journal:  Schizophr Bull       Date:  2016-03-15       Impact factor: 9.306

9.  Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study.

Authors:  Sameer Jauhar; Mattia Veronese; Matthew M Nour; Maria Rogdaki; Pamela Hathway; Federico E Turkheimer; James Stone; Alice Egerton; Philip McGuire; Shitij Kapur; Oliver D Howes
Journal:  Mol Psychiatry       Date:  2018-04-20       Impact factor: 15.992

Review 10.  Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies.

Authors:  John Lally; Olesya Ajnakina; Brendon Stubbs; Michael Cullinane; Kieran C Murphy; Fiona Gaughran; Robin M Murray
Journal:  Br J Psychiatry       Date:  2017-10-05       Impact factor: 9.319

View more
  5 in total

1.  A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance.

Authors:  Kun Yang; Luisa Longo; Zui Narita; Nicola Cascella; Frederick C Nucifora; Jennifer M Coughlin; Gerald Nestadt; Thomas W Sedlak; Marina Mihaljevic; Min Wang; Anshel Kenkare; Anisha Nagpal; Mehk Sethi; Alexandra Kelly; Pasquale Di Carlo; Vidyulata Kamath; Andreia Faria; Peter Barker; Akira Sawa
Journal:  Mol Psychiatry       Date:  2021-10-12       Impact factor: 13.437

2.  Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial.

Authors:  Archana Mishra; K H Reeta; Sudhir Chandra Sarangi; Rituparna Maiti; Mamta Sood
Journal:  Psychopharmacology (Berl)       Date:  2022-09-07       Impact factor: 4.415

3.  Increased brain gyrification and subsequent relapse in patients with first-episode schizophrenia.

Authors:  Daiki Sasabayashi; Yoichiro Takayanagi; Tsutomu Takahashi; Atsushi Furuichi; Haruko Kobayashi; Kyo Noguchi; Michio Suzuki
Journal:  Front Psychiatry       Date:  2022-08-10       Impact factor: 5.435

Review 4.  Magnetic resonance imaging of the dopamine system in schizophrenia - A scoping review.

Authors:  Julia Schulz; Juliana Zimmermann; Christian Sorg; Aurore Menegaux; Felix Brandl
Journal:  Front Psychiatry       Date:  2022-09-20       Impact factor: 5.435

5.  Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.

Authors:  Georgios Schoretsanitis; John M Kane; Christoph U Correll; Jose M Rubio
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 7.348

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.